Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

This study has been terminated.
(Business objectives have changed)
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT01620944
First received: June 13, 2012
Last updated: November 26, 2013
Last verified: November 2013
  Purpose

The primary objective of this study in antiretroviral (ARV)-naïve Human immunodeficiency virus 1 (HIV-1) ribonucleic acid infected subjects is to compare the response rate at Week 48 of a daily regimen of Atazanavir (ATV)/ Ritonavir (RTV)HS 300/100 mg combined with either one additional drug [Lamivudine (3TC) 300 mg daily] or 2 additional drugs [Tenofovir/Emtricitabine(TDF/FTC) 300/200 mg daily].


Condition Intervention Phase
HIV
Drug: Atazanavir
Drug: Ritonavir
Drug: Lamivudine
Drug: Tenofovir/Emtricitabine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 48-Week, Randomized, Open-Label Phase 3B Study Comparing the Antiviral Efficacy and Safety of ATV/RTV 3TC With ATV/RTV Plus TDF/FTC In HIV-1-Infected, Treatment-Naïve Subjects, Followed By a 48-Week Period on ATV/RTV Plus 3TC

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Proportion of subjects with HIV-1 RNA < 40 c/mL [ Time Frame: Week 48 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Proportion of subjects with HIV-1 RNA < 40 c/mL [ Time Frame: Week 96 ] [ Designated as safety issue: Yes ]
  • Proportion of subjects with HIV-1 RNA < 400 c/mL [ Time Frame: Weeks 48 and 96 ] [ Designated as safety issue: Yes ]
  • Incidence rates of SAEs and AEs leading to discontinuation through Weeks 48 and 96 [ Time Frame: Up to week 48 and week 96 ] [ Designated as safety issue: Yes ]
  • Changes from baseline in glomerular filtration rate (eGFR) and bone mineral density (BMD) [ Time Frame: Baseline (week 0), week 48 and week 96 ] [ Designated as safety issue: Yes ]
  • Incidence rates of newly emergent genotypic substitutions and phenotypic resistance to study drugs among subjects with virologic failure through Weeks 48 and 96 [ Time Frame: Up to week 48 and week 96 ] [ Designated as safety issue: Yes ]

Enrollment: 3
Study Start Date: July 2012
Estimated Study Completion Date: October 2016
Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm1: ATV/RTVHS+3TC Drug: Atazanavir
Capsule, oral, 300 mg, Once daily (QD), 96 weeks
Drug: Ritonavir
Tablets, oral, 100 mg, QD, 96 Weeks
Other Name: Ritonavir high sensitivity (RTV HS)
Drug: Lamivudine
Tablet, oral, 300 mg, QD, 96 Weeks
Active Comparator: Arm2: ATV/RTVHS+TDF/FTC Drug: Atazanavir
Capsule, oral, 300 mg, Once daily (QD), 96 weeks
Drug: Ritonavir
Tablets, oral, 100 mg, QD, 96 Weeks
Other Name: Ritonavir high sensitivity (RTV HS)
Drug: Tenofovir/Emtricitabine
Tablets, oral, 300/200 mg, QD, 48 Weeks

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed Written Informed Consent

    • Freely given informed consent must be obtained from subjects prior to clinical trial participation, including informed consent for any screening procedures conducted to establish subject eligibility for the trial
    • A freely given Pharmacokinetics (PK) sub-study consent form must be obtained from the subset of subjects participating in the intensive PK sub-study
  2. Target Population

    • Treatment-naive HIV-1-infected subjects (< 48 hours of any ARV is allowed)
    • Subjects who have an HIV-1 Ribonucleic acid (RNA) level ≥ 1000 c/mL at screening
    • Subjects who have a Antigenic marker of helper/inducer T lymphocytes (CD4) + cell count > 100 cells/mm3
  3. Age and Reproductive Status

    • Men and women, 18 years of age or older (or minimum age as determined by local regulatory or legal requirements)
    • Women of childbearing potential (WOCBP) must use highly effective methods of birth control for up to 8 weeks after the last dose of investigational product to minimize the risk of pregnancy. WOCBP must follow instructions for birth control for the entire duration of the study including a minimum of 30 days after dosing has been completed

Acceptable methods of highly effective birth control include:

  • Condom with spermicide
  • Diaphragm and spermicide
  • Cervical cap and spermicide

Since acceptable and available methods of contraception vary among different countries, participating women may choose their preferred contraceptive method atazanavir AI424494 BMS-232632 Clinical Protocol Date: 31-01-2012 33 based on physician recommendations. Caution is warranted with co-administration of oral contraceptives (ethinyl estradiol and norethindrone)

  • Women must have a negative serum or urine pregnancy test [minimum sensitivity 25 IU/L or equivalent units of Human chorionic gonadotropin (HCG)] within 24 hours prior to the start of investigational product
  • Women must not be breastfeeding
  • Sexually active fertile men must use highly effective birth control if their partners are WOCBP

Exclusion Criteria:

  1. Target Disease Exceptions

    • Subjects who have an HIV-1 RNA level ≥500,000 c/mL at screening
    • Screening HIV genotype showing resistance to any component of the study regimen (ATV, RTV, 3TC, TDF/FTC)
    • Previously documented HIV-2 infection
  2. Medical History and Concurrent Diseases

    • Acute or chronic hepatitis B virus (HBV) or Acute hepatitis C virus (HCV) co-infection

    Note - Chronic co-infection with hepatitis C is not exclusion criteria. Subjects with acute hepatitis C may have the option to be screened after the event has evolved into a chronic infection

    • Presence of a newly diagnosed HIV-related opportunistic infection (OI) or any medical condition requiring acute therapy at the time of enrollment. Subjects on stable maintenance therapy for an OI may be enrolled
    • Primary HIV infection
    • History or current cardiac disease, defined by presence of arrhythmias, ischemic disease, or a conduction abnormality including left bundle branch block (LBB) or left anterior fascicular block (LAFB), 2nd- or 3rd-degree atrioventricular block (AVB), or any cardiac abnormality deemed clinically significant by the investigator. In addition, the following Electrocardiogram (ECG) findings are exclusionary:

      • PR Interval > 260 msec (severe 1st degree AV Block)
      • QRS Interval > 120 msec
    • Moderate-to-severe hepatic insufficiency
    • Obstructive liver disease
    • Recent therapy with agents having significant systemic myelosuppressive, neurotoxic, pancreatotoxic, hepatotoxic or cytotoxic potential within 3 months of study start or the expected need for such therapy at the time of enrollment, or therapy with methadone or ribavirin/interferons or treatment with neurotoxic drugs or drugs that affect CYP3A4
    • Concomitant administration of a proton pump inhibitor (PPI) or H2 blocker or any other drug with potential interaction with the investigational products
    • Life expectancy < 1 year according to the judgment of the investigator
    • Active alcohol or substance use sufficient, in the investigator's opinion, to prevent adequate compliance with study therapy or to increase the risk of developing pancreatitis or chemical hepatitis
    • History or ongoing psychiatry disorder
    • Any other clinical conditions or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for study or unable to comply with the dosing requirements
  3. Physical and Laboratory Test Findings

    • Screening laboratory analysis shows any of the following abnormal laboratory results:

      • Grade IV glucose
      • Grade IV electrolytes
      • Grade IV transaminases
      • Grade IV hematology
    • Calculated creatinine clearance < 60 mL/min as estimated by the Cockcroft-Gault equation
  4. Allergies and Adverse Drug Reaction

    • Hypersensitivity to any component of the study drug formulations
  5. Sex and Reproductive Status

    • Pregnancy
  6. Other Exclusion Criteria

    • Prisoners or subjects who are involuntarily incarcerated
    • Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01620944

Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

No publications provided

Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT01620944     History of Changes
Other Study ID Numbers: AI424-494, 2011-006187-47
Study First Received: June 13, 2012
Last Updated: November 26, 2013
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board
European Union: European Medicines Agency

Additional relevant MeSH terms:
Emtricitabine
Ritonavir
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents

ClinicalTrials.gov processed this record on October 19, 2014